Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Boehringer Ingelheim
McKinsey
AstraZeneca

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for MT-1303

See Plans and Pricing

« Back to Dashboard

Drug Development Status for MT-1303: Sponsors, patents, clinical trial progress

MT-1303 is an investigational drug.

There have been 11 clinical trials for MT-1303. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2013.

The most common disease conditions in clinical trials are Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, and Crohn Disease. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Corporation and [disabled in preview].

There are seven US patents protecting this investigational drug and fifty-four international patents.

Recent Clinical Trials for MT-1303
TitleSponsorPhase
Extension Study of MT-1303 in Subjects With Crohn's DiseaseMitsubishi Tanabe Pharma CorporationPhase 2
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's DiseaseMitsubishi Tanabe Pharma CorporationPhase 2
Exploratory Study of MT-1303 in Systemic Lupus Erythematosus PatientsMitsubishi Tanabe Pharma CorporationPhase 1

See all MT-1303 clinical trials

Clinical Trial Summary for MT-1303

Top disease conditions for MT-1303
Top clinical trial sponsors for MT-1303

See all MT-1303 clinical trials

US Patents for MT-1303

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MT-1303   Start Trial Kinase inhibitors Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB)   Start Trial
MT-1303   Start Trial Kinase inhibitors Respivert Limited (N/A) Topivert Pharma Limited (London, GB)   Start Trial
MT-1303   Start Trial Sphingosine pathway modulating compounds for the treatment of cancers Enzo Biochem, Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
McKesson
Johnson and Johnson
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.